US approval upon success of ASCEND is not absolutely a sure thing, but close. Say Sept of next year. Presumably Intermune will bring a lot of sales people in from existing markets (esp Canada) to produce a good sell-in. Say $50-60 in two and a half years. The low risk-free rate of return makes that look especially good relative to cash today.